In an 87-year-old patient with a history of juvenile dermatomyositis and dementia, can duloxetine be discontinued?

Can Duloxetine Be Discontinued in This 87-Year-Old Patient?

Yes, duloxetine can and likely should be discontinued in this 87-year-old patient with dementia, particularly given the family's goals to reduce medication burden, but it must be tapered gradually over at least 2 weeks to avoid discontinuation syndrome.

Rationale for Discontinuation

In the context of deprescribing for older adults with dementia, duloxetine falls into a category where discontinuation should be strongly considered when:

• The medication burden needs reduction 1
• Goals of care are shifting toward comfort and quality of life
• The perceived benefit is unclear or minimal
• The patient has dementia with declining functionality 1

The 2021 Mayo Clinic polypharmacy guidelines specifically support deprescribing efforts in older adults with dementia, noting that it is "safe to taper to off, especially when there is perceived lack of benefit" 1. In long-term care settings, deprescribing medications may reduce mortality and falls by approximately 25% 1.

Critical Tapering Requirements

Abrupt discontinuation is contraindicated. The FDA label explicitly warns that duloxetine discontinuation syndrome occurs commonly, with symptoms including 2:

• Dizziness (most common at 12.4%)
• Nausea, headache, paresthesias
• Irritability, anxiety, insomnia
• Vomiting, hyperhidrosis, fatigue

Research confirms that 44.3% of patients experience discontinuation-emergent adverse events when duloxetine is stopped abruptly 3. However, 65% of these symptoms resolve within 7 days, and most are mild to moderate 3.

Specific Tapering Protocol

The FDA recommends gradual dose reduction over at least 2 weeks 2. A practical approach:

• Reduce dose by 25-50% every 1-2 weeks
• Monitor closely for discontinuation symptoms at each step
• If intolerable symptoms emerge, resume the previous dose temporarily, then taper more slowly
• Consider extending taper to 4 weeks or longer in patients on higher doses or with prior withdrawal sensitivity 3

Special Considerations in This Patient

Age-Related Factors

At 87 years old, this patient faces increased risks from duloxetine continuation 4:

• Falls risk: Duloxetine causes orthostatic hypotension and increases fall risk, which is particularly dangerous in elderly patients 2
• Cognitive effects: SNRIs can contribute to cognitive impairment in older adults
• Bleeding risk: Increased with concurrent NSAIDs or anticoagulants, common in elderly patients 2

Dementia Context

The presence of dementia strengthens the case for discontinuation 1:

• Medication burden reduction improves quality of life
• Anticholinergic and sedating effects worsen cognitive function
• Simplified medication regimens improve adherence and reduce caregiver burden

Juvenile Dermatomyositis History

While duloxetine may have been prescribed for chronic pain related to dermatomyositis, there is no evidence that inflammatory myopathies themselves contraindicate duloxetine discontinuation 5. If pain management remains necessary after discontinuation, consider 1, 4:

• Scheduled acetaminophen (safer in elderly)
• Topical agents
• Non-pharmacological approaches (physical therapy, heat/cold)

Monitoring During and After Discontinuation

Watch for:

• Discontinuation symptoms (first 1-2 weeks): dizziness, nausea, paresthesias, mood changes
• Return of original symptoms: If duloxetine was treating depression or pain, monitor for recurrence
• Behavioral changes: Particularly important in dementia patients

Common Pitfalls to Avoid

1. Abrupt cessation: Always taper, even if the patient or family wants rapid discontinuation
2. Inadequate monitoring: Check in at least weekly during the taper
3. Confusing withdrawal with disease progression: Discontinuation symptoms are time-limited and distinct from dementia progression
4. Restarting at full dose: If symptoms require resumption, restart at the last tolerated dose

When NOT to Discontinue

Reconsider discontinuation if:

• History of severe, treatment-resistant depression with prior suicide attempts
• Clear, ongoing benefit for neuropathic pain that significantly impacts quality of life
• Patient/family strongly oppose after informed discussion
• Active major depressive episode requiring treatment

In this case, given the advanced age, dementia, and family's desire to reduce medications, discontinuation with proper tapering is the appropriate clinical decision 1.